Hospital
Labette County Medical Center
Labette County Medical Center was paid $2.46M by Medicaid between Jan 2018 and Nov 2024, across 142 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoLABETTE COUNTY MEDICAL CENTER
PARSONS, KS 67357
PARSONS, KS 67357
33aNPI1578560421assigned 07/07/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.46M
24GClaims152,939
24DCodes billed142
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kansas
Rank by total paid#12 of 48
Median peer was paid$461K
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,400 | $465K | |
| 2019 | 30,018 | $451K | |
| 2020 | 20,186 | $395K | |
| 2021 | 19,728 | $357K | |
| 2022 | 20,044 | $342K | |
| 2023 | 18,641 | $230K | |
| 2024incomplete | 12,922 | $220K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 14,363 | 13,514 | $595K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 8,333 | 7,692 | $316K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.1% | 3,723 | 3,149 | $223K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 8.3% | 594 | 567 | $205K |
| 80053 | Comprehensive metabolic panel | 5.8% | 17,071 | 15,351 | $142K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.8% | 859 | 815 | $94K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.3% | 1,681 | 1,613 | $58K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 15,534 | 14,025 | $56K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.1% | 28 | 27 | $51K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.6% | 469 | 423 | $41K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 3,456 | 3,083 | $34K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.3% | 1,665 | 1,477 | $32K |
130 more codes
| 99285 | Emergency room visit (most serious) | 1.2% | 718 | $29K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.2% | 595 | $28K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 1,637 | $28K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 473 | $28K |
| 85027 | 1.1% | 3,030 | $27K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,292 | $22K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 513 | $22K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,378 | $21K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,253 | $20K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,075 | $20K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,393 | $20K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 678 | $18K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 855 | $17K |
| 84484 | <1% | 2,400 | $17K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 451 | $17K |
| 80164 | <1% | 1,785 | $16K | |
| 87400 | <1% | 1,731 | $15K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 469 | $14K |
| 81001 | <1% | 3,566 | $12K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 343 | $11K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,209 | $11K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 368 | $10K |
| 84439 | <1% | 1,758 | $8K | |
| 86140 | <1% | 1,313 | $8K | |
| 87040 | <1% | 772 | $8K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 79 | $8K |
| G0378 | Hospital observation service, per hour | <1% | 102 | $8K |
| 87486 | <1% | 594 | $7K | |
| 87581 | <1% | 594 | $7K | |
| 85007 | <1% | 2,854 | $7K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 112 | $6K |
| 74019 | <1% | 335 | $6K | |
| 80305 | <1% | 553 | $6K | |
| 80061 | Lipid panel | <1% | 791 | $6K |
| 83605 | <1% | 917 | $6K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,252 | $6K |
| 83880 | <1% | 343 | $5K | |
| 81003 | <1% | 3,441 | $4K | |
| 83655 | <1% | 281 | $4K | |
| 83690 | <1% | 743 | $4K | |
| 87807 | <1% | 208 | $4K | |
| 87420 | <1% | 284 | $4K | |
| 81025 | <1% | 405 | $3K | |
| 80081 | <1% | 29 | $3K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,883 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 295 | $3K |
| 87070 | <1% | 343 | $3K | |
| 85610 | <1% | 886 | $3K | |
| 0240U | <1% | 23 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 347 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 208 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,410 | $2K |
| 85730 | <1% | 703 | $2K | |
| 80306 | <1% | 142 | $2K | |
| 82728 | <1% | 100 | $2K | |
| 80074 | <1% | 83 | $2K | |
| 29580 | <1% | 30 | $2K | |
| 97597 | <1% | 27 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 120 | $2K |
| 86696 | <1% | 61 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 44 | $2K |
| 87634 | <1% | 30 | $2K | |
| 84146 | <1% | 110 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 131 | $1K |
| 85652 | <1% | 235 | $1K | |
| 86803 | <1% | 71 | $1K | |
| 87186 | <1% | 149 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 95 | $1K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 94 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 621 | $1K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 124 | $982.62 |
| 83721 | <1% | 206 | $956.80 | |
| 82607 | <1% | 132 | $950.72 | |
| 86850 | <1% | 122 | $944.88 | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 881 | $768.51 |
| 87077 | <1% | 113 | $764.44 | |
| 82746 | <1% | 97 | $736.35 | |
| 99070 | <1% | 170 | $736.01 | |
| 86901 | <1% | 125 | $675.00 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 15 | $586.35 |
| 73130 | <1% | 30 | $579.70 | |
| 86900 | <1% | 125 | $533.28 | |
| 97161 | <1% | 14 | $523.11 | |
| 86695 | <1% | 56 | $494.36 | |
| A0425 | Ground mileage, per statute mile | <1% | 1,618 | $488.18 |
| 83735 | <1% | 111 | $485.89 | |
| 87088 | <1% | 83 | $480.05 | |
| 82150 | <1% | 59 | $471.33 | |
| 83615 | <1% | 94 | $467.52 | |
| 84703 | <1% | 45 | $448.39 | |
| 73562 | <1% | 15 | $356.55 | |
| 97010 | <1% | 42 | $327.25 | |
| 73610 | <1% | 15 | $309.45 | |
| 80320 | <1% | 14 | $238.93 | |
| 84436 | <1% | 25 | $222.71 | |
| 82550 | <1% | 43 | $220.36 | |
| 72100 | <1% | 13 | $211.38 | |
| 73030 | <1% | 12 | $204.25 | |
| 87340 | <1% | 13 | $197.31 | |
| 93017 | <1% | 12 | $186.78 | |
| 84702 | <1% | 13 | $136.30 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,400 | $135.36 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 167 | $129.15 |
| 85018 | <1% | 74 | $125.33 | |
| 84466 | <1% | 13 | $122.30 | |
| 86787 | <1% | 13 | $119.69 | |
| 86762 | <1% | 12 | $111.90 | |
| 82950 | <1% | 13 | $108.15 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 26 | $104.47 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 158 | $100.66 |
| 86592 | <1% | 14 | $85.40 | |
| 83540 | <1% | 28 | $72.34 | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 30 | $53.76 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 72 | $47.58 |
| 84550 | <1% | 16 | $41.85 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 53 | $37.21 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 14 | $36.42 |
| 82948 | <1% | 14 | $20.79 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 27 | $15.19 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 16 | $13.29 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 21 | $9.19 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12 | $6.87 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 48 | $0.62 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 38 | $0.33 |
| 84479 | <1% | 14 | $0.31 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 151 | $0.20 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 150 | $0.00 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 398 | $0.00 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 25 | $0.00 |
| A9270 | Non-covered item or service | 0% | 496 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSOPER, JANET (CFO)
| Provider | Location | Paid |
|---|---|---|
| Labette County Medical Center | Parsons, KS | $6.50M |
| Labette County Medical Center | Parsons, KS | $668K |
| Labette County Medical Center | Parsons, KS | $591K |
| Labette County Medical Center | Parsons, KS | $163K |
| Labette County Medical Center | Parsons, KS | $25K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.